The decline in vaccine sales was primarily due to lower sales of its RSV vaccine Arexvy that fell 72% during the quarter. This downtick can be attributed to the restrictive recommendation issued ...

The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease by a low-single digit percentage. GSK's (GSK) shares are falling 4% in premarket trading ...

So the pipeline is strengthening. The Arexvy development is disappointing for GSK shareholders, as it seemed like a new high-growth market. RSV is a common winter illness and revenue from this new ...

However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and delayed ...

(RTTNews) - Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE after the British drug maker reported Wednesday ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...